Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vietnam Health Official Concerned About Safety Of GSK H1N1 Vaccine

This article was originally published in PharmAsia News

Executive Summary

A Vietnamese health official said he is concerned about possible cases of anaphylaxis and other severe adverse effects from the 1.2 million doses of H1N1 flu vaccine ordered

You may also be interested in...



BioNTech Looks To AI Partnership To Accelerate Drug Discovery

The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.

Genmab Accelerates Priority Candidates, Ends Enapotamab Vedotin Development

Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.

Novartis CEO Touts R&D 'Wild Cards' As Proof Of Deep Pipeline

Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan. 

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel